Cartilage Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cartilage diseases markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.9 Billion by 2034, exhibiting a growth rate (CAGR) of 11.64% during 2024-2034.
The cartilage diseases market has been comprehensively analyzed in IMARC's new report titled "Cartilage Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cartilage diseases encompass a range of conditions that affect the crucial connective tissue present in various parts of the body, primarily providing structural support and facilitating smooth joint movement. These disorders can manifest in numerous ways depending on the affected area, such as the articular cartilage in joints or the cartilage in the respiratory tract. The common symptoms of the illnesses include joint pain, inflammation, stiffness, reduced range of motion, etc. In some cases, individuals suffering from the diseases might experience a grating sensation within their joints during movement. Additionally, impaired cartilage in the respiratory tract can lead to breathing difficulties and various other pulmonary symptoms. The diagnosis of these ailments often involves a combination of medical history assessment, physical examination, and imaging techniques. X-rays, MRI scans, and arthroscopy are commonly recommended to visualize cartilage damage and assess its severity. Early detection and accurate prognosis are essential to preventing further deterioration and managing symptoms effectively.
The increasing prevalence of several associated risk factors, like advancing age, genetic mutations, trauma, injuries, joint instability, obesity, chronic inflammation, etc., is primarily driving the cartilage diseases market. In addition to this, the inflating utilization of advanced treatments, such as matrix-induced autologous chondrocyte implantation and osteochondral graft transplantation, is also creating a positive outlook for the market. These approaches focus on the specific damaged area while preserving healthy cartilage tissue in surrounding regions. Moreover, the widespread adoption of non-surgical therapies, including physiotherapy and hyaluronic acid injections, which aim to reduce pain, improve joint function, and delay the need for surgical interventions, is further bolstering the market growth. Apart from this, the rising usage of biologically active agents, such as growth factors and stem cells, that help in cartilage regeneration and repair is acting as another significant growth-inducing factor. Additionally, the escalating demand for minimally invasive arthroscopic techniques, since they allow for better treatment outcomes in patients, is also augmenting the market growth. Furthermore, the emerging popularity of gene therapy, which introduces beneficial genes into cells to correct or modify the genetic aberrations linked to cartilage degeneration, is expected to drive the cartilage diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cartilage diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cartilage diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cartilage diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cartilage diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cartilage diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cartilage diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cartilage diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cartilage diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cartilage diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cartilage diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of cartilage diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cartilage diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cartilage diseases across the seven major markets?
What is the size of the cartilage diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cartilage diseases?
What will be the growth rate of patients across the seven major markets?
Cartilage Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cartilage diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cartilage diseases market?
What are the key regulatory events related to the cartilage diseases market?
What is the structure of clinical trial landscape by status related to the cartilage diseases market?
What is the structure of clinical trial landscape by phase related to the cartilage diseases market?
What is the structure of clinical trial landscape by route of administration related to the cartilage diseases market?
The cartilage diseases market has been comprehensively analyzed in IMARC's new report titled "Cartilage Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cartilage diseases encompass a range of conditions that affect the crucial connective tissue present in various parts of the body, primarily providing structural support and facilitating smooth joint movement. These disorders can manifest in numerous ways depending on the affected area, such as the articular cartilage in joints or the cartilage in the respiratory tract. The common symptoms of the illnesses include joint pain, inflammation, stiffness, reduced range of motion, etc. In some cases, individuals suffering from the diseases might experience a grating sensation within their joints during movement. Additionally, impaired cartilage in the respiratory tract can lead to breathing difficulties and various other pulmonary symptoms. The diagnosis of these ailments often involves a combination of medical history assessment, physical examination, and imaging techniques. X-rays, MRI scans, and arthroscopy are commonly recommended to visualize cartilage damage and assess its severity. Early detection and accurate prognosis are essential to preventing further deterioration and managing symptoms effectively.
The increasing prevalence of several associated risk factors, like advancing age, genetic mutations, trauma, injuries, joint instability, obesity, chronic inflammation, etc., is primarily driving the cartilage diseases market. In addition to this, the inflating utilization of advanced treatments, such as matrix-induced autologous chondrocyte implantation and osteochondral graft transplantation, is also creating a positive outlook for the market. These approaches focus on the specific damaged area while preserving healthy cartilage tissue in surrounding regions. Moreover, the widespread adoption of non-surgical therapies, including physiotherapy and hyaluronic acid injections, which aim to reduce pain, improve joint function, and delay the need for surgical interventions, is further bolstering the market growth. Apart from this, the rising usage of biologically active agents, such as growth factors and stem cells, that help in cartilage regeneration and repair is acting as another significant growth-inducing factor. Additionally, the escalating demand for minimally invasive arthroscopic techniques, since they allow for better treatment outcomes in patients, is also augmenting the market growth. Furthermore, the emerging popularity of gene therapy, which introduces beneficial genes into cells to correct or modify the genetic aberrations linked to cartilage degeneration, is expected to drive the cartilage diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cartilage diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cartilage diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cartilage diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cartilage diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cartilage diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cartilage diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cartilage diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cartilage diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cartilage diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cartilage diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of cartilage diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cartilage diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cartilage diseases across the seven major markets?
What is the size of the cartilage diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cartilage diseases?
What will be the growth rate of patients across the seven major markets?
Cartilage Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cartilage diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cartilage diseases market?
What are the key regulatory events related to the cartilage diseases market?
What is the structure of clinical trial landscape by status related to the cartilage diseases market?
What is the structure of clinical trial landscape by phase related to the cartilage diseases market?
What is the structure of clinical trial landscape by route of administration related to the cartilage diseases market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CARTILAGE DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CARTILAGE DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CARTILAGE DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CARTILAGE DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CARTILAGE DISEASES - UNMET NEEDS
10 CARTILAGE DISEASES - KEY ENDPOINTS OF TREATMENT
11 CARTILAGE DISEASES - MARKETED PRODUCTS
11.1 List of Cartilage Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Olumiant (Baricitinib) - Eli Lilly and Company/Incyte Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Celebrex (Celecoxib) - Astellas Pharma/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Motrin (Ibuprofen) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Kevzara (Sarilumab) - Regeneron/Sanofi
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CARTILAGE DISEASES - PIPELINE DRUGS
12.1 List of Cartilage Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CARTILAGE DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CARTILAGE DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CARTILAGE DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cartilage Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cartilage Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cartilage Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cartilage Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cartilage Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cartilage Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cartilage Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cartilage Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cartilage Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cartilage Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cartilage Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cartilage Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cartilage Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cartilage Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cartilage Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cartilage Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cartilage Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cartilage Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cartilage Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cartilage Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cartilage Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cartilage Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cartilage Diseases - Access and Reimbursement Overview
16 CARTILAGE DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CARTILAGE DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CARTILAGE DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CARTILAGE DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CARTILAGE DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CARTILAGE DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CARTILAGE DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CARTILAGE DISEASES - UNMET NEEDS
10 CARTILAGE DISEASES - KEY ENDPOINTS OF TREATMENT
11 CARTILAGE DISEASES - MARKETED PRODUCTS
11.1 List of Cartilage Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Olumiant (Baricitinib) - Eli Lilly and Company/Incyte Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Celebrex (Celecoxib) - Astellas Pharma/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Motrin (Ibuprofen) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Kevzara (Sarilumab) - Regeneron/Sanofi
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CARTILAGE DISEASES - PIPELINE DRUGS
12.1 List of Cartilage Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CARTILAGE DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CARTILAGE DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CARTILAGE DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cartilage Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cartilage Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cartilage Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cartilage Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cartilage Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cartilage Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cartilage Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cartilage Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cartilage Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cartilage Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cartilage Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cartilage Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cartilage Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cartilage Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cartilage Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cartilage Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cartilage Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cartilage Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cartilage Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cartilage Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cartilage Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cartilage Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cartilage Diseases - Access and Reimbursement Overview
16 CARTILAGE DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CARTILAGE DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CARTILAGE DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
